Suzanne M de la Monte Selected Research

Amyloid beta-Peptides

1/2017	Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease.
1/2009	Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease.
4/2007	Nitric oxide synthase 3-mediated neurodegeneration after intracerebral gene delivery.
3/2006	Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease.
2/2005	Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Suzanne M de la Monte Research Topics

Disease

45	Insulin Resistance 01/2023 - 02/2005
36	Alzheimer Disease (Alzheimer's Disease) 08/2023 - 01/2002
21	Inflammation (Inflammations) 01/2023 - 08/2008
16	Cognitive Dysfunction 08/2023 - 12/2005
14	Fatty Liver 01/2022 - 01/2009
13	Fetal Alcohol Spectrum Disorders 04/2023 - 06/2007
13	Mitochondrial Diseases (Mitochondrial Disease) 01/2023 - 06/2003
10	Neoplasms (Cancer) 04/2022 - 07/2002
8	Type 2 Diabetes Mellitus (MODY) 01/2012 - 09/2008
7	Neuroinflammatory Diseases 08/2023 - 01/2012
7	Obesity 01/2023 - 09/2008
6	Diabetes Mellitus 01/2023 - 02/2005
6	Alcoholic Liver Diseases (Alcoholic Liver Disease) 01/2022 - 08/2007
6	Atrophy 12/2017 - 01/2012
6	Alcoholism (Alcohol Abuse) 05/2016 - 09/2008
5	Dementia (Dementias) 04/2022 - 01/2002
5	Hepatocellular Carcinoma (Hepatoma) 09/2015 - 05/2006
4	Metabolic Diseases (Metabolic Disease) 01/2016 - 01/2012
4	Alcoholic Fatty Liver 08/2011 - 01/2009
4	Carcinoma (Carcinomatosis) 05/2009 - 07/2002
3	Gliosis 01/2019 - 03/2006
3	Parkinson Disease (Parkinson's Disease) 01/2019 - 01/2009
3	Hypoxia (Hypoxemia) 12/2016 - 09/2010
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2012 - 11/2008
3	Muscular Diseases (Myopathy) 01/2012 - 08/2007
3	Cholangiocarcinoma 01/2007 - 05/2003
2	Peripheral Nervous System Diseases (PNS Diseases) 04/2022 - 01/2012
2	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 04/2022 - 02/2005
2	Long Term Adverse Effects 01/2022 - 01/2016
2	Infections 01/2021 - 02/2003
2	Brain Injuries (Brain Injury) 01/2020 - 07/2019
2	Non-alcoholic Fatty Liver Disease 01/2018 - 04/2012
2	Fibrosis (Cirrhosis) 01/2013 - 01/2010
2	Spontaneous Abortion (Miscarriage) 03/2010 - 01/2007
2	Adenocarcinoma 05/2009 - 07/2002
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2007 - 07/2002
2	Neuroblastoma 12/2006 - 07/2002
1	Central Nervous System Diseases (CNS Diseases) 06/2023
1	Chronic Disease (Chronic Diseases) 04/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 04/2022
1	Congenital Abnormalities (Deformity) 04/2022

Drug/Important Bio-Agent (IBA)

56	Insulin (Novolin)FDA Link 01/2023 - 02/2005
26	Ethanol (Ethyl Alcohol)IBA 04/2023 - 06/2007
24	Insulin-Like PeptidesIBA 01/2023 - 02/2005
19	CeramidesIBA 02/2014 - 01/2009
17	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2002
16	LipidsIBA 01/2022 - 01/2009
14	NitrosaminesIBA 01/2020 - 01/2009
11	aspartic acid 2-oxoglutarate-dependent dioxygenaseIBA 09/2010 - 07/2002
9	CytokinesIBA 08/2023 - 01/2009
9	Mixed Function Oxygenases (Monooxygenases)IBA 01/2017 - 08/2006
8	Biomarkers (Surrogate Marker)IBA 08/2023 - 01/2002
8	Streptozocin (Streptozotocin)FDA Link 12/2019 - 02/2005
8	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2010 - 12/2005
7	Insulin ReceptorIBA 01/2017 - 02/2005
6	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 12/2005
6	UbiquitinIBA 01/2019 - 06/2003
6	SmokeIBA 07/2016 - 01/2016
5	Amyloid beta-PeptidesIBA 01/2017 - 02/2005
5	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2016 - 01/2010
5	Insulin-Like Growth Factor I (IGF-1)IBA 01/2010 - 02/2005
4	Messenger RNA (mRNA)IBA 01/2021 - 05/2006
4	Nicotine FDA Link 01/2016 - 03/2015
4	KetonesIBA 01/2016 - 03/2015
3	thermozymocidin (myriocin)IBA 01/2022 - 10/2013
3	Amyloid (Amyloid Fibrils)IBA 01/2012 - 04/2007
3	Therapeutic UsesIBA 01/2012 - 01/2009
3	Insulin-Like Growth Factor II (Somatomedin A)IBA 12/2011 - 02/2005
2	ChemokinesIBA 08/2023 - 01/2018
2	Agent OrangeIBA 01/2023 - 04/2022
2	Phospholipids (Phosphatides)FDA LinkGeneric 01/2022 - 12/2017
2	ApolipoproteinsIBA 11/2020 - 12/2019
2	Jagged-1 ProteinIBA 01/2017 - 09/2010
2	Aspartic Acid (Aspartate)FDA Link 12/2016 - 01/2016
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 06/2016 - 01/2016
2	GhrelinIBA 05/2016 - 11/2014
2	Choline O-Acetyltransferase (Choline Acetyltransferase)IBA 01/2016 - 09/2008
2	3-nitrotyrosineIBA 11/2015 - 06/2012
2	Transcription Factors (Transcription Factor)IBA 11/2015 - 09/2010
2	AcetylcholinesteraseIBA 11/2015 - 01/2012
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2013 - 12/2006
2	Glycogen Synthase KinasesIBA 01/2013 - 03/2006
2	Sphingomyelin Phosphodiesterase (Sphingomyelinase)IBA 04/2012 - 12/2011
2	Neurotransmitter Agents (Neurotransmitter)IBA 03/2012 - 03/2011
2	Triglycerides (Triacylglycerol)IBA 12/2011 - 01/2009
2	IGF Type 2 Receptor (Insulin-Like-Growth-Factor II Receptor)IBA 04/2011 - 01/2010
2	RNA (Ribonucleic Acid)IBA 03/2011 - 01/2007
2	Glycoproteins (Glycoprotein)IBA 01/2010 - 12/2003
2	Glycogen Synthase Kinase 3 betaIBA 06/2009 - 09/2008
2	Monoclonal AntibodiesIBA 05/2009 - 07/2002
2	Amyloid beta-Protein Precursor (Amyloid Protein Precursor)IBA 01/2009 - 06/2003
2	AD7c-NTPIBA 06/2004 - 01/2002
1	Choline (Choline Chloride)IBA 04/2023
1	IsoflavonesIBA 04/2023
1	Sirolimus (Rapamycin)FDA Link 01/2023
1	2,4-Dichlorophenoxyacetic Acid (2,4 Dichlorophenoxyacetic Acid)IBA 01/2023
1	2,4,5-Trichlorophenoxyacetic Acid (2,4,5-T)IBA 01/2023

Therapy/Procedure

9	Therapeutics 01/2023 - 01/2009
1	Lasers (Laser) 06/2023
1	General Anesthesia 01/2023